April 24, 2012—Providing more guidance to clinicians on the provision of optimal patient care, the American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and American Medical Association–convened Physician Consortium for Performance Improvement (AMA-PCPI) released a publication highlighting updated performance measures for adults with heart failure (HF). The 2011 performance measures include care provided in both the outpatient and inpatient setting, emphasizing the need to measure care quality over time and across providers, while also focusing on patient outcomes.

April 24, 2012 - SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO) — a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO) — reported that it has completed enrollment for its “InterSEPT” (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.

April 23, 2012 - Boston Scientific Corp. announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release. This prospective, single-arm feasibility study enrolled 11 patients at three sites in Australia. Results from the REPRISE I trial are scheduled to be presented at the EuroPCR Congress in May.